Scientific Presentations & Publications
The mechanistic rationale of zotiraciclib is supported by strong activity both in vitro and in vivo.
In vitro studies of zotiraciclib, the Adastra lead product candidate, demonstrated reduced tumor cell growth when combined with radiotherapy in glioma models.
In vivo studies demonstrate increased survival of tumor-bearing mouse models treated with zotiraciclib + temozolomide (TMZ), and interim Phase 1b (NCI) results demonstrate safety and suggest promising efficacy in recurrent high-grade gliomas.
Zotiraciclib plus temozolomide demonstrates tolerable safety and efficacy signal for recurrent anaplastic astrocytoma & glioblastoma in adults
Zotiraciclib, a novel multi-kinase inhibitor, is effiective in pediatric brain tumors, with selective potency in those with MYC expression
Zotiraciclib, a brain penetrant multi-CDK inhibitor inhibits growth in MYC-driven glioblastoma
Zotiraciclib, an oral CDK inhibitor, induces cell death in human glioma cell lines and glioma-initiating cells